- Home
- AACT vs ABCL Comparison
AACT vs ABCL Comparison
Compare AACT & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AACT
- ABCL
- Stock Information
- Founded
- AACT 2021
- ABCL 2012
- Country
- AACT United States
- ABCL Canada
- Employees
- AACT N/A
- ABCL N/A
- Industry
- AACT
- ABCL Biotechnology: Pharmaceutical Preparations
- Sector
- AACT
- ABCL Health Care
- Exchange
- AACT Nasdaq
- ABCL Nasdaq
- Market Cap
- AACT 697.5M
- ABCL 772.9M
- IPO Year
- AACT 2023
- ABCL 2020
- Fundamental
- Price
- AACT $11.28
- ABCL $2.01
- Analyst Decision
- AACT
- ABCL Buy
- Analyst Count
- AACT 0
- ABCL 3
- Target Price
- AACT N/A
- ABCL $7.50
- AVG Volume (30 Days)
- AACT 1.3M
- ABCL 4.0M
- Earning Date
- AACT 01-01-0001
- ABCL 05-08-2025
- Dividend Yield
- AACT N/A
- ABCL N/A
- EPS Growth
- AACT 15.24
- ABCL N/A
- EPS
- AACT 0.42
- ABCL N/A
- Revenue
- AACT N/A
- ABCL $28,833,000.00
- Revenue This Year
- AACT N/A
- ABCL N/A
- Revenue Next Year
- AACT N/A
- ABCL $36.62
- P/E Ratio
- AACT $27.15
- ABCL N/A
- Revenue Growth
- AACT N/A
- ABCL N/A
- 52 Week Low
- AACT $10.58
- ABCL $1.89
- 52 Week High
- AACT $11.29
- ABCL $4.34
- Technical
- Relative Strength Index (RSI)
- AACT 64.78
- ABCL 33.61
- Support Level
- AACT $11.25
- ABCL $2.45
- Resistance Level
- AACT $11.29
- ABCL $2.64
- Average True Range (ATR)
- AACT 0.03
- ABCL 0.14
- MACD
- AACT 0.00
- ABCL -0.06
- Stochastic Oscillator
- AACT 88.89
- ABCL 3.60
About AACT Ares Acquisition Corporation II
Ares Acquisition Corp II is a blank check company.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.